Record growth, guidance beat track solid—defense upside requires years
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade A
Hit FY27 interim targets, confident on beat, clear on near-term. No prior misses flagged.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered 69% YoY growth and 80% PAT growth with margin expansion (29% EBITDA), on track to beat ₹14,000 Cr FY27 guidance. Large order book (₹20,178 Cr) and structural defense opportunity (Pinaka, Bhargavastra) underpin long-term. Key risk: major defense programs are 2–3 years to commercialization; external headwinds (commodity, supply chain) could compress margins.
₹3518.9 Cr
Revenue · +69% YoY₹650 Cr
Reported PAT · +79.7% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Domestic explosives stand at 29%, up from 27%
METDomestic mix 29% vs 27% prior year—exact call figures
International explosives 43%, down from 46% YoY
METInternational 43% vs 46% prior year—call exact
Defense revenue 29% of mix, up from 24%
METDefense ₹1,002 Cr = 29% of ₹3,519 Cr Q2; prior year 24%
Will surpass ₹14,000 Cr FY27 guidance
METH1 ₹7,187 Cr on track; Q2 monsoon-impacted (-4.1% QoQ), H2 expected stronger; pace supports beat
Margins to reach 28–30%, expecting ~29% FY27
METH1 EBITDA margin 28.45%, Q2 at 29.02%; full-year ~29% is realistic vs 28% prior guidance
Earnings quality
What changed since the last call
Defense revenue mix expanded
UpgradeDefense now 29% of revenue (₹1,002 Cr Q2) vs 24% prior year; tracking to ₹4,500 Cr FY27 on path
FY27 margin outlook raised modestly
UpgradeExpecting 28–30% (avg ~29%) vs prior 28% guidance; H1 EBITDA margin 28.45%, Q2 at 29.02%
International 43%, domestic recovered
NeutralInternational 43% (vs 46% prior, -300 bps) but domestic 29% (vs 27%, +200 bps); domestic demand pickup compensated
No FY28/29 guidance quantified
WithdrawnManagement explicitly said will provide multi-year targets only after FY27 close; deferred clarity
The Q&A
Analysts probed defense timelines, Omnia integration, MALE UAV status, margin sustainability, capacity constraints. Management candid on trials (Pinaka/Bhargavastra 2–3 years to commercialization), deferred Omnia updates, acknowledged MALE UAV news drought but stayed confident on execution. Held firm on ₹14,000 Cr beat.
Domestic non-defense growth — Amit Dixit, Goldman Sachs
AnsweredGrowth momentum will be better in H2. Monsoon impact Q2; coal mining demand good. Expect strong domestic growth H2 also. Demand outlook positive.
Pinaka order status — Amit Dixit, Goldman Sachs
AnsweredPinaka order ~₹3,000 Cr expected, negotiation ongoing. Received bid ~1.5 years back. In final negotiation stage now. Order book given best price, expect conclusion very soon.
155mm shells capacity — Amit Anwani, PL Capital
AnsweredEstablishing 155mm facility, set up already. Want to scale up to 155mm vertical. Established counter-drone systems in Indian market, will help break international orders. Pinaka supplies ongoing.
Missile tech/MALE UAV — Vikash Singh, ICICI Securities
AnsweredMissile tech opportunity aligned with Solar's capabilities (energetic materials, propellants, warheads, rocket integration). One of most competent private partners for tactical missile programs. MALE UAV: news dried up; no current procurement impact.
Defense capability gaps — Amit Mahawar, UBS Securities
AnsweredDefense complex; in it 15 years. Always challenging to adopt new technologies. At Solar, integrated large facilities handling all ammunition types. Focusing on developing programs with DRDO. Continuous process finding gaps. Confident should adopt new things, offer smart products.
FY27 guidance beat & margins — Tanmay, Aditya Birla Sun Life
AnsweredWill definitely surpass ₹14,000 Cr FY27 guidance. H1 always weaker, H2 better. Domestic now 27–28%, will deliver more H2. Margins will cross 29% on average. Defense at ₹1,000 Cr Q2, ₹900 Cr prior Q = ₹1,900–₹2,000 Cr H1 total; expect ₹4,500 Cr FY27. Surpass guidance on top line.
Bhargavastra trials timeline — Pinakin, HSBC
AnsweredBhargavastra: like said, internal trials calendar year and field trial also calendar year. Once complete, commercialization starts. Years to reach commercialization stage. Huge demand for such products.
Omnia acquisition clarity — Pinakin, HSBC
PartialOmnia detailed call couple months back, no more updates at this stage. Questions can be answered once acquisition is completed.
155mm shells delivery timelines — Kavish Parekh, 360 ONE Capital
PartialShare at appropriate stage on 155mm program. Total order book defense ~₹18,000 Cr, most from international markets. Will address 155mm program at right time. Variety of products in order book including 155mm products.
Volume growth outlook & capex — Kavish Parekh, 360 ONE Capital
AnsweredCapacity expansion in different parts of country for growing domestic demand, especially housing/infrastructure/coal mining. Industry growth ~6–7%, our volume growth 10–15% range. Will be enhanced by capability & capacity expansion.
Defense/export business outlook — Amit Mahawar, UBS Securities
DodgedThis call is for quarterly/half-yearly results. Will provide full clarity on FY27 results. Cannot give guidance for FY28/29 yet due to uncertainties (geopolitical, supply chain, commodity). Will restrict discussion to Q2 H1 FY27 results.
International order book detail — Tanmay, Aditya Birla Sun Life
PartialSupply to 90+ countries. Inquiries practically from every nation allowed by Government of India. 20,178 Cr order book, defense ~₹17,568 Cr. Getting inquiries & orders from various countries. Cannot disclose details per confidentiality.
Guidance
FY27: ₹14,000 Cr+ (will 'surpass' baseline target)
HighH1 ₹7,187 Cr on pace. Q2 monsoon-impacted (-4.1% QoQ); H2 seasonally stronger. Beat implied by management.
FY27: 28–30% EBITDA margin, expecting ~29% avg
HighH1 EBITDA margin 28.45%, Q2 at 29.02%. Prior target 28%; upside now 28–30%. Defense upside to benefit margins.
Greenfield expansion ongoing; no specific FY27 capex target disclosed
MediumPrior FY27 guidance was ₹2,050 Cr capex. Expansion in domestic capacity (155mm shells facility, ammunition lines) underway.
Risks the call surfaced
Defense program execution
HighPinaka (₹3,000 Cr expected) and Bhargavastra (₹3,000+ Cr) still in trial phase. Commercialization 2–3 years out. RFP conversion uncertain; contract finalization can take years.
Commodity & supply chain
MediumGeopolitical issues, supply chain disruptions, commodity price volatility acknowledged. Could compress EBITDA margins (target 28–30%) if unabated.
International market exposure
MediumInternational explosives 43% of revenue; 90+ countries served but specifics withheld for confidentiality. Exports subject to GOI restrictions. Geopolitical shifts could limit market access.
Domestic market cyclicality
MediumDomestic explosives 29% of revenue; demand tied to coal mining, infrastructure investment. Monsoon impact Q2 evident (-4.1% QoQ). Slowdown could compress H2 growth.
Omnia acquisition
LowOmnia (agri-explosives) acquisition pending approvals. No updates provided; contingent on regulatory/antitrust clearance. Delays could defer accretive revenue.
Management
Score 8/10. Clear on Q2 numbers and segment splits. Candid on defense program timelines (2–3 years to commercialization). Deferred FY28/29 guidance citing uncertainty—prudent, not evasive. Q2 beat FY27 interim targets (revenue ₹3,519 Cr on guidance), margins 29% (vs 28% prior). H1 on pace to beat ₹14,000 Cr FY27. No material misses flagged.
1 · H2 FY27
Seasonal demand recovery (monsoon over), higher revenue expected vs Q2; on track for ₹14,000+ Cr beat
2 · FY28–FY29
Defense program commercialization (Pinaka, Bhargavastra); RFP flow expected post trials
3 · CY2026–2027
Omnia acquisition close (pending approvals); agri-explosives portfolio addition
Key risk: major defense programs are 2–3 years to commercialization; external headwinds (commodity, supply chain) could compress margins.
Informational and educational content only. Not investment advice.